Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 9, 458–459 (1 July 2009) | doi:10.1038/nrc2686
Drug resistance: Getting through
Abstract
Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis owing to several factors that include a poor response to chemotherapy. This is strange given that pancreatic tumour cells in vitro and mice with pancreatic cancer xenografts respond to the standard chemotherapeutic gemcitabine.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
